HC Wainwright set a $4.00 price target on Cytori Therapeutics (NASDAQ:CYTX) in a research report report published on Monday morning. The firm currently has a buy rating on the biotechnology company’s stock.
A number of other brokerages have also recently issued reports on CYTX. Maxim Group set a $5.00 price objective on Cytori Therapeutics and gave the company a buy rating in a research note on Monday, January 22nd. ValuEngine upgraded Cytori Therapeutics from a strong sell rating to a sell rating in a research note on Friday, February 2nd. Laidlaw restated a buy rating and issued a $1.65 price objective on shares of Cytori Therapeutics in a research note on Thursday, February 22nd. Zacks Investment Research cut Cytori Therapeutics from a hold rating to a sell rating in a research note on Thursday, March 8th. Finally, B. Riley upgraded Cytori Therapeutics from a neutral rating to a buy rating in a research note on Friday, March 9th. Two research analysts have rated the stock with a sell rating and four have given a buy rating to the company. The stock has a consensus rating of Hold and an average price target of $2.23.
Shares of Cytori Therapeutics opened at $0.29 on Monday, Marketbeat Ratings reports. Cytori Therapeutics has a 52-week low of $0.27 and a 52-week high of $0.28.
A hedge fund recently raised its stake in Cytori Therapeutics stock. Perkins Capital Management Inc. raised its stake in shares of Cytori Therapeutics (NASDAQ:CYTX) by 134.0% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,136,041 shares of the biotechnology company’s stock after buying an additional 1,223,046 shares during the quarter. Perkins Capital Management Inc. owned about 6.08% of Cytori Therapeutics worth $644,000 at the end of the most recent reporting period. 5.93% of the stock is owned by institutional investors.
About Cytori Therapeutics
Cytori Therapeutics, Inc, a therapeutics company, together with its subsidiaries, develops regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for various medical conditions. Its lead drug candidate, ATI-0918, is a generic version of pegylated liposomal encapsulated doxorubicin, which is in Phase III clinical trial and used for various cancer types.
Receive News & Ratings for Cytori Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.